Analysis of the blood level of micafungin involving patients with hematological diseases: New findings regarding combination therapy with tacrolimus

被引：26

作者：

Shimoeda, S ^{[1
]}

Ohta, S

Kobayashi, H

Saitou, H

Kubota, A

Yamato, S

Shimada, K

Sasaki, M

Kawano, K

机构：

[1] Nagano Res Cross Hosp, Dept Pharm, Nagano, Japan

[2] Nagano Red Cross Hosp, Dept Internal Med 1, Nagano 3808582, Japan

[3] Niigata Univ Pharm & Appl Sci, Dept Pharmaceut & Analyt Chem, Niigata, Japan

[4] Niigata Univ Pharm & Appl Life Sci, Dept Clin Pharmaceut, Niigata 9502081, Japan

来源：

BIOLOGICAL & PHARMACEUTICAL BULLETIN | 2005年 / 28卷 / 03期

关键词：

micafungin; blood level; tacrolimus; hematological disease; Aspergillus;

D O I：

10.1248/bpb.28.477

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In 29 patients (40 samples) with hematological diseases who had been treated with a candin antifungal agent, micafungin (MCFG), we measured the blood level of MCFG by high-performance liquid chromatography (HPLC). There was a correlation between the dose and the blood level of MCFG (r=0.729,p < 0.001). In addition, there was a correlation between the total bilirubin level and the CID value (r=0.458, p < 0.01), which was calculated by dividing the blood level of MCFG by the dose, although there was no correlation between creatinine clearance and the C/D value. These findings suggest that the dose of MCFG must be regulated in patients with biliary stasis-type liver hypofunction. In addition, there was no significant difference in the blood level of MCFG between the group in which tacrolimus (FK506) was combined with MCFG and the group in which MCFG alone was administered. These results suggest that there are no changes in the blood level of MCFG even when MCFG is combined with FK506.

引用

页码：477 / 480

页数：4